Eloxx Pharmaceuticals, Inc. (ELOX): Price and Financial Metrics


Eloxx Pharmaceuticals, Inc. (ELOX): $3.31

0.15 (+4.75%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ELOX Stock Price Chart Interactive Chart >

Price chart for ELOX

ELOX Price/Volume Stats

Current price $3.31 52-week high $24.60
Prev. close $3.16 52-week low $1.70
Day low $3.13 Volume 13,300
Day high $3.44 Avg. volume 142,631
50-day MA $3.77 Dividend yield N/A
200-day MA $7.42 Market Cap 7.17M

Eloxx Pharmaceuticals, Inc. (ELOX) Company Bio


Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is based in Waltham, Massachusetts.


ELOX Latest News Stream


Event/Time News Detail
Loading, please wait...

ELOX Latest Social Stream


Loading social stream, please wait...

View Full ELOX Social Stream

Latest ELOX News From Around the Web

Below are the latest news stories about ELOXX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ELOX as an investment opportunity.

Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it will present at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13th at 12:00 PM ET. A live webcast of the presentation and a replay of the presentation will be available on the Company’s website at https://investors.eloxxpharma.com/events-presentations. About Eloxx Pharmaceuticals Eloxx

Yahoo | March 6, 2023

Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed

Topline results expected in first half of 2023WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first patients have now been dosed in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations. Topline results are expected in the first half of 2023. “Patients with Alport syndrome with nonsense mutations lack disea

Yahoo | February 27, 2023

Eloxx Pharmaceuticals making progress on Phase 2 clinical study for ELX-02 Alport syndrome candidate

Eloxx Pharmaceuticals president and CEO Sumit Aggarwal joins Proactive's Natalie Stoberman to discuss the latest update on the clinical study for its lead investigational product candidate ELX-02.

Yahoo | February 24, 2023

Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome

Topline results expected in first half of 2023 Trial sites open in Australia and United Kingdom WATERTOWN, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first patients have now been enrolled in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations. “With enrollment of the first patients in our Phase 2 study of ELX-0

Yahoo | January 25, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

The final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday!

William White on InvestorPlace | January 6, 2023

Read More 'ELOX' Stories Here

ELOX Price Returns

1-mo N/A
3-mo 55.40%
6-mo -51.24%
1-year -82.01%
3-year -96.72%
5-year -99.08%
YTD 81.87%
2022 -93.56%
2021 -82.26%
2020 -45.92%
2019 -38.72%
2018 50.13%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7419 seconds.